Dr. Nicolas Girard, Professor of Respiratory Medicine at Versailles Saint Quentin University and head of the Curie-Montsouris Thorax Institute discusses his presentation at ESMO 2023 – Presidential Symposium / Abstract #LBA5 – Amivantamab plus carboplatin/pemetrexed vs carboplatin/pemetrexed as first line treatment in EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): primary results from PAPILLON, a randomized phase 3 global study.

Nicolas Girard is a pneumologist specializing in thoracic oncology, for the treatment of patients with lung cancer or rare thoracic cancers. He is experienced in the treatment of thymic tumors—thymomas and thymic carcinomas—as part of his work in the RYTHMIC network. He is domain leader for rare thoracic cancers for the European Reference Network EURACAN.

Nicolas Girard is involved in several clinical and translational research projects aiming at improving the treatment of these cancers. He is the Président of the International Thymic Malignancy Interest Group.

He is Professor of Respiratory Medicine at Versailles Saint Quentin University. He is the Head of the Curie-Montsouris Thorax Institute.

Liked it? Take a second to support healthprofessionalradio on Patreon!